Einstein A Go-Go: Professor Sharon Lewin Discusses Australia’s Infectious Diseases Response
Professor Sharon Lewin, Director at The Peter Doherty Institute for Infection and Immunity, joins the program for a wide-ranging discussion about vaccines and Australia’s management of infectious diseases. She reflects on her last 18 months in the Doherty Institute and the impact its research had on Australia’s management of COVID-19, as well as the future of Australia’s infectious diseases response.
Photo: supplied
Melbourne s rapidly spreading syphilis outbreak may have been sparked by dating apps dailymail.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailymail.co.uk Daily Mail and Mail on Sunday newspapers.
The early immune response in a person who has been vaccinated for COVID-19 can predict the level of protection they will have to the virus over time, according to analysis from Australian mathematicians, clinicians, and scientists, and published the journal Nature Medicine. The researchers from the University of New South Wales s Kirby Institute, the Peter Doherty Institute for Infection and Immunity, and the University of Sydney have identified an immune correlate of vaccine protection. This has the potential to dramatically cut development times for new vaccines, by measuring neutralising antibody levels as a proxy for immune protection from COVID-19. Neutralising antibodies are tiny Y-shaped proteins produced by our body in response to infection or vaccination. They bind to the virus, reducing its ability to infect, says Dr Deborah Cromer from the Kirby Institute.
Researchers identify a new way to predict the efficacy of COVID-19 vaccines
The early immune response in a person who has been vaccinated for COVID-19 can predict the level of protection they will have to the virus over time, according to analysis from Australian mathematicians, clinicians, and scientists, and published today in
Nature Medicine.
The researchers from UNSW s Kirby Institute, the Peter Doherty Institute for Infection and Immunity, and the University of Sydney have identified an immune correlate of vaccine protection. This has the potential to dramatically cut development times for new vaccines, by measuring neutralising antibody levels as a proxy for immune protection from COVID-19.